Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.